Profile banner
Jagadesh Earla

Jagadesh Earla

Outcomes research leader in oncology and health economics

jagadeshe
Rahway, United States
Joined March 2026
Favicon imageorcid.org
Favicon imageresearchgate.net
Favicon imageslideshare.net

Network

1.6K connections
📈
HEOR Pharma Leaders
🔬
Academic HEOR Researchers
🏥
Health System Leaders
🎓
UH Pharmacy Faculty
📊
Real World Evidence
🤝
HEOR Consultants
🌐
ISPOR Community

Summary

Experienced outcomes research and HEOR scientist with a focus on oncology and real-world evidence generation. theorg+2
Active contributor to professional society work and methodological projects in outcomes research, particularly digital health and standardization of terminology. ispor
Academic background rooted in pharmacy and health outcomes: PharmD and MBA training followed by a PhD in Health Outcomes & Policy Research. orcid+1
Bridges clinical practice and industry research—experience ranges from clinical pharmacist and medical writing to HEOR roles in biopharma. researchgate+1

Work

Education

Projects

Writing

Treatment, Outcomes, and Resource Utilization Among Patients With Metastatic Breast and Advanced Epithelial Ovarian Cancer, by BRCA1/2 and HRD Status

January 1, 2025

Manuscript reporting differences in treatment, outcomes, and healthcare resource utilization by BRCA1/2 and HRD status among patients with metastatic breast and advanced epithelial ovarian cancer.

Favicon imagetempus.com

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase (PARP) Inhibitor Use and Outcomes (ASCO/PO abstract/publication)

January 1, 2025

Abstract/publication on real-world germline BRCA testing and PARP inhibitor use and outcomes (ASCO publication record lists Jagadeswara R. Earla as a contributor).

Favicon imageascopubs.org

Use of disease modifying agents in patients with multiple sclerosis: Analysis of ten years of national data

January 1, 2020

Cross-sectional analysis using NAMCS data (2006–2015) examining prescribing patterns and trends of disease modifying agents for multiple sclerosis, including factors associated with DMA prescribing.

Favicon imagepubmed.ncbi.nlm.nih.gov

PND104 COMPARATIVE ADHERENCE TRAJECTORIES OF ORAL FINGOLIMOD AND INJECTABLE DISEASE MODIFYING AGENTS IN MULTIPLE SCLEROSIS

January 1, 2020

Comparative adherence trajectories study presented as a conference abstract/poster on adherence to oral vs injectable disease modifying agents in multiple sclerosis.

Favicon imageresearchgate.net